<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="182228">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722228</url>
  </required_header>
  <id_info>
    <org_study_id>0359-08-HMO-CTIL</org_study_id>
    <nct_id>NCT00722228</nct_id>
  </id_info>
  <brief_title>Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      This study is based on the finding that tumor cells that are grown in the laboratory can be
      modified in such a way that, when injected to the patient, they will stimulate his/her
      immune response. This approach will be evaluated in patients with colorectal, gastric,
      ovarian, breast or lung epithelial cancer. Tumor cells grown in the laboratory will be
      modified to make them stimulatory to the immune system, irradiated to kill them, and
      injected to the patient eight times at two-week intervals . This protocol is expected to
      prolong survival of metastatic epithelial cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Colorectal Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic epithelial cancer

          -  Above 18 years of age

          -  Failure of at least one chemotherapy protocol

          -  Clinical performance status of ECOG 0,1

          -  Absolute neutrophil count greater than 1000/mm3

          -  Serum ALT/AST less than three times the upper limit of normal

          -  Serum creatinine less than or equal to 1.6 mg/dl.

          -  Must be able to understand and sign the Informed Consent document

        Exclusion Criteria:

          -  Below 18 years of age

          -  Women who are pregnant

          -  Life expectancy of less than three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arik , Tzukert, DMD</last_name>
    <phone>: 00 972 2 6776095</phone>
    <email>arik@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hadas , Lemberg, PhD</last_name>
    <phone>00 972 2 6777572</phone>
    <email>: lhadas@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tamar Peretz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <lastchanged_date>July 24, 2008</lastchanged_date>
  <firstreceived_date>July 23, 2008</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
